ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.25−0.08 (-0.71%)
Close on Nov 18, 2026Market cap $102.18MP/E 140.6Yield –
ImmuCell operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
ImmuCell's operating income for the twelve months ending Jun 30, 2026 was $3.87M, up 123.0% year over year. For fiscal 2025 it was $1.65M. Over ten years it grew -2.5% a year on average. The highest annual figure on record is $2.12M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.65M | – |
| FY2024 | Dec 31, 2024 | -$1.64M | – |
| FY2023 | Dec 31, 2023 | -$5.75M | – |
| FY2022 | Dec 31, 2022 | -$2.30M | -993.2% |
| FY2021 | Dec 31, 2021 | $257.39K | – |
| FY2020 | Dec 31, 2020 | -$1.38M | – |
| FY2019 | Dec 31, 2019 | -$953.91K | – |
| FY2018 | Dec 31, 2018 | -$1.45M | – |
| FY2017 | Dec 31, 2017 | -$242.85K | -127.3% |
| FY2016 | Dec 31, 2016 | $890.20K | -58.1% |
| FY2015 | Dec 31, 2015 | $2.12M | – |
| FY2014 | Dec 31, 2014 | -$206.40K | – |
| FY2013 | Dec 31, 2013 | -$19.55K | -108.0% |
| FY2012 | Dec 31, 2012 | $245.00K | – |
| FY2011 | Dec 31, 2011 | -$632.73K | – |
| FY2010 | Dec 31, 2010 | -$690.28K | – |
| FY2009 | Dec 31, 2009 | -$529.91K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.93M | +239.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.97M | +76.2% |
| Q4 FY2025 | Dec 31, 2025 | -$57.96K | -109.3% |
| Q3 FY2025 | Sep 30, 2025 | $20.08K | – |
| Q2 FY2025 | Jun 30, 2025 | $569.56K | – |
| Q1 FY2025 | Mar 31, 2025 | $1.12M | – |
| Q4 FY2024 | Dec 31, 2024 | $621.40K | – |
| Q3 FY2024 | Sep 30, 2024 | -$574.89K | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.39M | – |
| Q1 FY2024 | Mar 31, 2024 | -$300.05K | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.18M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.30M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.26M | -495.4% |
| Q4 FY2022 | Dec 31, 2022 | -$1.63M | -1223.5% |
| Q3 FY2022 | Sep 30, 2022 | -$616.79K | -327.5% |
| Q2 FY2022 | Jun 30, 2022 | -$619.01K | -387.2% |
| Q1 FY2022 | Mar 31, 2022 | $570.61K | – |
| Q4 FY2021 | Dec 31, 2021 | $145.41K | – |
| Q3 FY2021 | Sep 30, 2021 | $271.09K | – |
| Q2 FY2021 | Jun 30, 2021 | $215.51K | – |
| Q1 FY2021 | Mar 31, 2021 | -$374.63K | -290.3% |
| Q4 FY2020 | Dec 31, 2020 | -$634.36K | – |
| Q3 FY2020 | Sep 30, 2020 | -$251.60K | – |
| Q2 FY2020 | Jun 30, 2020 | -$691.27K | – |
| Q1 FY2020 | Mar 31, 2020 | $196.88K | -25.8% |
| Q4 FY2019 | Dec 31, 2019 | -$242.47K | – |
| Q3 FY2019 | Sep 30, 2019 | -$429.82K | – |
| Q2 FY2019 | Jun 30, 2019 | -$546.93K | – |
| Q1 FY2019 | Mar 31, 2019 | $265.30K | – |
| Q4 FY2018 | Dec 31, 2018 | -$925.87K | – |
| Q3 FY2018 | Sep 30, 2018 | -$149.14K | – |
| Q2 FY2018 | Jun 30, 2018 | -$193.41K | – |
| Q1 FY2018 | Mar 31, 2018 | -$178.16K | -119.4% |
| Q4 FY2017 | Dec 31, 2017 | -$413.34K | -446.4% |
| Q3 FY2017 | Sep 30, 2017 | -$482.41K | -1055.9% |
| Q2 FY2017 | Jun 30, 2017 | -$265.31K | – |
| Q1 FY2017 | Mar 31, 2017 | $918.21K | – |
| Q4 FY2016 | Dec 31, 2016 | $119.31K | – |
| Q3 FY2016 | Sep 30, 2016 | $50.47K | – |
See a number that looks wrong?